VLDL Particle Number Test

You can have a routine cholesterol panel that looks acceptable and still be carrying a high number of fat-rich particles in your blood that quietly drive heart disease and metabolic dysfunction. VLDL particle number (very-low-density lipoprotein particle number) counts these particles directly, giving you a read on a piece of cardiovascular risk that traditional lipid testing tends to underestimate.

This number rises early in insulin resistance, abdominal obesity, and fatty liver, often before blood sugar or standard lipids drift. It is most useful when paired with apoB (apolipoprotein B, the total count of all artery-damaging particles) to understand both how many atherogenic particles you carry and where those particles are coming from.

What VLDL Particles Actually Are

VLDL particles are made by your liver to ship triglycerides (the fats you eat or store) out to muscle, fat, and other tissues. They circulate carrying both triglycerides and cholesterol, and over time they get processed into the smaller particles you may know as LDL (low-density lipoprotein). Every VLDL particle carries one copy of a protein called apoB, the same marker that labels LDL particles, so VLDL is part of the larger family of artery-damaging lipoproteins.

When you have more VLDL particles than your body can clear, the leftovers (called remnants) stay in your blood and can lodge in artery walls, where they contribute to plaque. Higher VLDL particle counts also reflect how hard your liver is working to export fat, which is why this number tends to climb with abdominal obesity, insulin resistance, and fatty liver.

Heart Disease Risk

In a study of 27,673 healthy women, higher VLDL particle counts were linked to a roughly 1.7 times higher risk of cardiovascular events when comparing the top fifth to the bottom fifth of values. In a separate analysis of statin-treated adults at high cardiovascular risk, each standard step up in the smallest VLDL particles (the cholesterol-rich remnants) was tied to a 68% higher risk of cardiovascular events, even when LDL cholesterol was already low.

Postmenopausal women whose LDL cholesterol was on target but whose VLDL cholesterol was elevated had thicker artery walls in the neck, an early sign of atherosclerosis. In adolescents and young adults, VLDL and LDL particle counts and sizes predicted blood vessel structure and stiffness better than traditional cholesterol numbers.

Insulin Resistance and Type 2 Diabetes

VLDL particles are some of the earliest lipid changes when insulin stops working properly. In a 5,314-person multi-ethnic cohort followed for the development of diabetes, a higher count of large VLDL particles and a larger average VLDL size were strong predictors of who went on to develop type 2 diabetes, independent of standard glucose and insulin markers.

In a 4,818-person Dutch cohort (the PREVEND study), people with more large, triglyceride-rich lipoproteins were more likely to develop diabetes years later, while those with larger LDL particles had lower risk. In patients with established type 2 diabetes and women with newly diagnosed gestational diabetes, VLDL particle count and size tracked closely with insulin resistance, while standard markers like HbA1c (a three-month average of blood sugar) and hs-CRP (a marker of inflammation) did not.

Peripheral Artery Disease

Peripheral artery disease (narrowing of arteries in the legs) is often missed by standard cholesterol testing. In a prospective study of 27,888 women, higher concentrations of large and medium VLDL particles were associated with future peripheral artery disease, even when LDL cholesterol looked acceptable. This is one of the clearest examples of a vascular outcome where particle counts add information that LDL-C alone misses.

How VLDL Particle Number Compares to ApoB

In a UK Biobank analysis of more than 207,000 adults, the total count of artery-damaging particles (apoB) was tied to a 33% higher risk of coronary artery disease per step up, and the specific mix of VLDL versus LDL particles within that total mattered very little. A separate analysis of nearly 430,000 people came to the same conclusion: the number of apoB-containing particles, regardless of type, is what tracks most closely with heart attack risk.

This is not a contradiction with the VLDL findings above. It means VLDL particles are atherogenic on a per-particle basis, but in most people they are a small fraction of total atherogenic particles, so apoB captures most of the risk. Where VLDL-P adds value is in identifying the metabolic phenotype behind the risk: very high VLDL-P relative to LDL-P points squarely at insulin resistance, fatty liver, and triglyceride-rich lipoprotein overproduction, which changes what you should focus on to lower your risk.

Reference Ranges

There are no universally accepted clinical cutpoints for VLDL particle number. The ranges below are drawn from research populations using nuclear magnetic resonance (NMR) lipoprotein profiling, the most common method for measuring this particle count. Ranges differ between labs and between assay platforms, so compare your numbers within the same lab over time rather than treating any single threshold as absolute.

Source: Patterns synthesized from Santisteban et al. (2025), Mackey et al. (MESA, 2015), Mora et al. (2009), and Witt et al. (2025).

When Results Can Be Misleading

• Recent meals: A high-fat meal raises VLDL and triglyceride levels for hours afterward, with larger increases in people who already have high triglycerides. Get this test fasting (8 to 12 hours without food) unless your lab specifies otherwise.
• Acute exercise: Intense aerobic exercise within the prior day can transiently lower large and medium VLDL particles. Wait at least 24 to 48 hours after a hard workout before testing.
• Sex and body composition: Women have substantially lower VLDL particle counts than men, even when matched on body fat percentage, so direct numerical comparisons across sexes can be misleading.
• Acute illness or surgery: Inflammation and metabolic stress can shift lipoprotein profiles unpredictably. Postpone testing until you are at least several weeks past an acute illness or hospital stay.

Tracking Your Trend

VLDL particle number is best understood as a trend, not a single snapshot. Day-to-day biology, recent meals, and exercise all create some variability, even though the laboratory measurement itself is quite reproducible (analytical variation under 4% for total VLDL particle count in NMR testing). A single high reading can be a fluke. A pattern of high readings, especially with rising triglycerides or elevated apoB, is a signal worth acting on.

Get a baseline. If you are making changes (weight loss, dietary shifts, starting a statin or other lipid medication), retest in 3 to 6 months to see whether the intervention is moving the number. If your levels are in a healthy range and your weight and lifestyle are stable, recheck at least annually as part of a broader cardiometabolic panel. The most useful comparison is your own number over time, measured by the same lab.

What to Do If Your Number Is High

An elevated VLDL particle count should trigger a deeper look at your metabolic health, not just your cholesterol. Order apoB to count total atherogenic particles, fasting triglycerides, fasting insulin and glucose to assess insulin resistance, HbA1c, and liver enzymes (ALT and AST, which can signal fatty liver). Lipoprotein(a) is worth checking once in your lifetime regardless, since it adds independent inherited risk.

If the pattern points to insulin resistance and elevated triglyceride-rich lipoproteins, the priorities are different from someone with high LDL cholesterol alone: weight loss, reducing refined carbohydrates and alcohol, increasing physical activity, and, for some, prescription therapy aimed at triglycerides and remnant particles. If your apoB is also high, a lipidologist or cardiologist can help decide whether lipid-lowering medication is appropriate. Do not wait for your standard cholesterol panel to confirm a problem the particle count is already showing.